Delaware
|
001-32954
|
20-0077155
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
2537 Research Boulevard, Suite 201
Fort Collins, CO 80526
|
||
(Address of Principal Executive Offices and zip code)
|
||
(888) 613-8802
|
||
(Registrant's Telephone Number, Including Area Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.005
|
STAB
|
NASDAQ Capital Market
|
Item 4.01
|
Changes in Registrant’s Certifying Accountant
|
Item 9.01
|
Financial Statements and Exhibits
|
Exhibit
Number
|
Description
|
16.1
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
Statera BioPharma, Inc.
|
|
|
|
|
|
|
Date: September 29, 2021
|
By:
|
/s/ Peter Aronstam
|
|
|
Name:
|
Peter Aronstam
|
|
|
Title:
|
Chief Financial Officer
|
|
Exhibit 16.1
September 29, 2021
Securities and Exchange Commission
100 F Street NE
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4.01 of Statera BioPharma, Inc.’s Form 8-K dated September 28, 2021, and have the following comments:
1. |
We agree with the statements made in paragraphs one through four discussing Statera BioPharma, Inc.’s relationship with Meaden & Moore, Ltd. |
2. |
We have no basis on which to agree or disagree with the statements made in paragraph five. |
Yours truly,
Meaden & Moore, Ltd.
Meaden & Moore, Ltd.
(A Meaden & Moore Affiliate Company)
1375 East Ninth Street, Suite 1800 | Cleveland, OH 44114-1790 | P (216) 241-3272 | F (216) 771-4511 | meadenmoore.com